Compositions and methods of treatment comprising amoxicillin and potassium clavulante with xanthan

Abstract

Bacterial infections may be treated using a high dosage regimen of amoxicillin and potassium clavulanate. Preferably, the dosage is provided by a bilayer tablet.

1  to  22 . (canceled)  
   
   
       23 . A composition comprising amoxicillin and potassium clavulanate in a dosage of 2000 mg of amoxycillin and 125 mg of potassium clavulanate, wherein the composition is in a solid form and comprises a first release phase and a second release phase; the first release phase comprising potassium clavulanate and a first part of amoxicillin; and the second release phase comprising a second amount of amoxicillin in the form of a soluble salt at about 60-80% of the second phase a pharmaceutically acceptable organic acid in a molar ratio of 50:1 to 1:5 (amoxicillin to organic acid, and a reduced amount of pharmaceutically acceptable release retarding polymer which is xanthan gum at about 1-5% of the second phase; wherein the composition provides a mean maximum plasma concentration (Cmax) of amoxicillin of at least 12 μg/ml.  
   
   
       24 - 68 . (canceled)  
   
   
       69 . A composition according to  claim 23  wherein the xanthan gum is pharmaceutical grade xanthan gum, 200 mesh.  
   
   
       70 . A composition according to  claim 23  wherein the amoxicillin in the first release phase is amoxicillin trihydrate.  
   
   
       71 . A composition according to  claim 23  wherein the soluble salt of amoxicillin in the second release phase is sodium amoxicillin.  
   
   
       72 . A composition according to  claim 71  wherein the sodium amoxicillin is crystallized sodium amoxicillin.  
   
   
       73 . A composition according to  claim 23  wherein the composition provides an Area under the Curve (AUC) value of amoxicillin which is at least 80% of that of the same amount if taken as an immediate release formulation over the same dosage period.  
   
   
       74 . A composition according to  claim 23  wherein the composition provides a mean plasma concentration of amoxicillin of at least 4 μg/ml for at least 4.4 hours  
   
   
       75 . A composition according to  claim 23  wherein the ratio of amoxicillin in the first and second release phases is from 3:1 to 1:3.  
   
   
       76 . A composition according to  claim 23  wherein the ratio of amoxicillin in the first and second release phases is from 3:1 to 2:3.  
   
   
       77 . A composition according to  claim 23  wherein the ratio of amoxicillin in the first and second release phases is from 2:1 to 2:3.  
   
   
       78 . A composition according to  claim 23  wherein the ratio of amoxicillin in the first and second release phases is from 3:2 to 1:1.  
   
   
       79 . A composition according to  claim 23  wherein the solid form is a tablet.  
   
   
       80 . A composition according to  claim 79  wherein the tablet is a bilayer tablet.  
   
   
       81 . A composition according to  claim 23  wherein the first release phase comprises essentially all the potassium clavulanate.  
   
   
       82 . A composition according to  claim 23  wherein the release of amoxicillin has a biphasic profile.  
   
   
       83 . A method for treating a bacterial infection in a patient in need thereof comprising administering to said patient an effective amount of a formulation according to  claim 23 .  
   
   
       84 . A method according to  claim 83  in which the bacterial infection is caused by at least one of the organisms  S. pneumoniae, H. influenzae,  and  M. catarrhalis.    
   
   
       85 . A method according to  claim 84  wherein the  S. pneumoniae  are Drug Resistant  S. pneumoniae  and Penicillin Resistant  S. pneumoniae  organisms.  
   
   
       86 . A method according to  claim 83  wherein the bacterial infection is a respiratory tract infection.  
   
   
       87 . A method according to  claim 86  wherein the respiratory tract infection is community acquired pneumoniae (CAP), acute exacerbation of chronic bronchitis (AECB), or acute bacterial sinusitis (ABS).  
   
   
       88 . A method according to  claim 83  wherein the formulation is administered over 7 to 14 days.  
   
   
       89 . The composition of  claim 23  wherein the pharmaceutically acceptable organic acid is in a molar ratio of 20:1 to 1:2 (amoxicillin to organic acid).  
   
   
       90 . The composition of  claim 23  wherein the pharmaceutically acceptable organic acid is selected from mono-carboxylic acids and poly-carboxylic acids having from 2 to 25 carbon atoms, monocyclic and polycyclic aryl acids, and monohydrogen, dihydrogen metal salts of multi-valent acids.  
   
   
       91 . The composition of  claim 90  wherein the pharmaceutically acceptable organic acid is selected from malonic acid, succinic acid, fumaric acid, maleic acid, adipic acid, lactic acid, levulinic acid, sorbic acid, or a fruit acid such as tartaric acid, malic acid, ascorbic acid, and citric acid.  
   
   
       92 . The composition of  claim 91  wherein the pharmaceutically acceptable organic acid is citric acid.  
   
   
       93 . The composition of  claim 92  wherein the sodium amoxicillin and citric acid are in a molar ratio of 20:1 to 1:2.  
   
   
       94 . The composition of  claim 93  wherein the sodium amoxicillin is about 438 mg±5%, citric acid is about 78 mg±10%, and xanthan gum is about 2% by weight.